CY1121382T1 - Ποσοτικοποιηση υπολειμματικων ενωσεων γλυκανης με μη-αναγωγικα ακρα - Google Patents

Ποσοτικοποιηση υπολειμματικων ενωσεων γλυκανης με μη-αναγωγικα ακρα

Info

Publication number
CY1121382T1
CY1121382T1 CY20181101201T CY181101201T CY1121382T1 CY 1121382 T1 CY1121382 T1 CY 1121382T1 CY 20181101201 T CY20181101201 T CY 20181101201T CY 181101201 T CY181101201 T CY 181101201T CY 1121382 T1 CY1121382 T1 CY 1121382T1
Authority
CY
Cyprus
Prior art keywords
glucane
quantification
residual
compounds
tips
Prior art date
Application number
CY20181101201T
Other languages
English (en)
Inventor
Brett E. Crawford
Jillian R. Brown
Charles A. Glass
Jim R. Beitel
Robin M. Jackman
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of CY1121382T1 publication Critical patent/CY1121382T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/40—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving amylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Παρέχονται στο παρόν μέθοδοι διάγνωσης ή παρακολούθησης της αντιμετώπισης μη-φυσιολογικής συσσώρευσης γλυκανών ή μιας διαταραχής η οποία συνδέεται με μη-φυσιολογική συσσώρευση γλυκανών.
CY20181101201T 2009-01-02 2018-11-13 Ποσοτικοποιηση υπολειμματικων ενωσεων γλυκανης με μη-αναγωγικα ακρα CY1121382T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14229109P 2009-01-02 2009-01-02
US16436509P 2009-03-27 2009-03-27
US23807909P 2009-08-28 2009-08-28
US12/649,110 US8232073B2 (en) 2009-01-02 2009-12-29 Quantification of non-reducing end glycan residual compounds
PCT/US2009/069944 WO2010078514A2 (en) 2009-01-02 2009-12-31 Quantification of non-reducing end glycan residual compounds

Publications (1)

Publication Number Publication Date
CY1121382T1 true CY1121382T1 (el) 2020-05-29

Family

ID=42310624

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181101201T CY1121382T1 (el) 2009-01-02 2018-11-13 Ποσοτικοποιηση υπολειμματικων ενωσεων γλυκανης με μη-αναγωγικα ακρα

Country Status (14)

Country Link
US (6) US8232073B2 (el)
EP (2) EP2376916B1 (el)
CA (1) CA2786114C (el)
CY (1) CY1121382T1 (el)
DK (1) DK2376916T3 (el)
ES (1) ES2694047T3 (el)
HK (1) HK1243768A1 (el)
HR (1) HRP20181685T1 (el)
HU (1) HUE040146T2 (el)
LT (1) LT2376916T (el)
PL (1) PL2376916T3 (el)
PT (1) PT2376916T (el)
SI (1) SI2376916T1 (el)
WO (1) WO2010078514A2 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523330A (ja) * 2000-02-04 2003-08-05 チルドレンズ・ホスピタル・リサーチ・ファウンデイション アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US8809009B2 (en) 2009-01-02 2014-08-19 Biomarin Pharmaceutical Inc. Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
US8232073B2 (en) * 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
MX338426B (es) 2010-04-23 2016-04-15 Synageva Biopharma Corp Enzima de enfermedad del almacenamiento lisosomico.
NZ700824A (en) 2010-09-09 2016-03-31 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
ES2704104T3 (es) * 2012-09-27 2019-03-14 Biomarin Pharm Inc Cuantificación de compuestos residuales de glicano con extremos no reductores
CN112986429B (zh) * 2013-09-05 2024-03-29 华盛顿大学商业中心 用于筛查mps i、ii、iiia、iiib、iva、vi和vii的试剂和方法
US10538794B2 (en) 2016-11-29 2020-01-21 Emory University Oligosaccharide libraries and methods of production
US12020820B1 (en) 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en) 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185245A (en) 1989-02-24 1993-02-09 Thomas Jefferson University Immumoassays and kit for detection of proteoglycans
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
ATE200580T1 (de) 1996-08-17 2001-04-15 Aventis Behring Gmbh Verfahren zur quantifizierung von glykosaminoglykanen in antithrombin iii-haltigen lösungen
AU774650B2 (en) 1999-03-26 2004-07-01 University Of Texas System, The Modulators of polysaccharides and uses thereof
US20050159343A1 (en) 1999-03-26 2005-07-21 Board Of Regents, University Of Texas System Inhibitors of glycosaminoglycans
US6852696B2 (en) 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
WO2001031044A1 (en) * 1999-10-26 2001-05-03 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Gonadotrophins in plants
DE60035285T2 (de) 1999-10-26 2008-02-21 Plant Research International B.V. Glykolisierung des säugetiertyps in pflanzen
US6936424B1 (en) * 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
MXPA02012032A (es) 2000-06-07 2003-04-25 Univ Duke Metodos de diagnostico de la enfermedad de pompe y otras enfermedades por almacenamiento de glucogeno.
WO2003068919A2 (en) 2002-02-12 2003-08-21 The Regents Of The University Of California Non-invasive method for measuring rates of biosynthesis of biological molecules by label incorporation
EP1497650A4 (en) 2002-04-30 2008-04-02 Seikagaku Kogyo Co Ltd METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASES
AUPS293002A0 (en) 2002-06-14 2002-07-04 Women's And Children's Hospital Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
AU2002950878A0 (en) 2002-08-20 2002-09-12 Proteome Systems Intellectual Property Pty Ltd Method for diagnosing disorders
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20050238536A1 (en) 2004-04-21 2005-10-27 Striepeke Steven K Device and method for measuring glycosaminoglycans in body fluids
US7651847B2 (en) * 2004-06-22 2010-01-26 The Regents Of The University Of California Methods of oligosaccharide profiling for the detection of cancer
US7582737B2 (en) 2004-07-20 2009-09-01 Academia Sinica Orthogonally protected disaccharide building blocks for synthesis of heparin oligosaccharides
US7892752B2 (en) * 2005-04-26 2011-02-22 Dwek Raymond A Glycosylation markers for cancer diagnosing and monitoring
FI20055417A0 (fi) 2005-07-20 2005-07-20 Glykos Finland Oy Syöpäpesifiset glykaanit ja niiden käyttö
JP4965999B2 (ja) * 2005-12-27 2012-07-04 セント ルイス ユニバーシティ ムコ多糖症の診断方法
EP2008096A2 (en) * 2006-04-03 2008-12-31 Massachusetts Institute of Technology Glycomic patterns for the detection of disease
GB0610350D0 (en) 2006-05-25 2006-07-05 Univ Liverpool prevention and/or treatment of neuodegenerative disorders
CA2729766A1 (en) 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
US8183003B2 (en) 2009-01-02 2012-05-22 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8809009B2 (en) * 2009-01-02 2014-08-19 Biomarin Pharmaceutical Inc. Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
US8592140B2 (en) 2009-01-02 2013-11-26 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US8232073B2 (en) * 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US20100248365A1 (en) 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
EP2411529A4 (en) 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc MODULATORS OF BIOSYNTHESIS OF N-BOUND GLYCANS
US20120295890A1 (en) 2009-12-31 2012-11-22 Zacharon Pharmaceutical, Inc. Glycosaminoglycan inhibitors
US20180092923A1 (en) * 2015-04-15 2018-04-05 Biomarin Pharmaceutical Inc. Methods for treating lysosomal storage disorders

Also Published As

Publication number Publication date
LT2376916T (lt) 2018-12-10
PT2376916T (pt) 2018-11-20
US9677116B2 (en) 2017-06-13
EP2376916B1 (en) 2018-10-03
EP2376916A4 (en) 2012-09-05
SI2376916T1 (sl) 2019-01-31
DK2376916T3 (en) 2018-11-26
CA2786114A1 (en) 2010-07-08
US8232073B2 (en) 2012-07-31
EP2376916A2 (en) 2011-10-19
US20160153024A1 (en) 2016-06-02
US9222120B2 (en) 2015-12-29
US8771974B2 (en) 2014-07-08
PL2376916T3 (pl) 2019-03-29
CA2786114C (en) 2018-09-25
WO2010078514A2 (en) 2010-07-08
US10793894B2 (en) 2020-10-06
US20100173337A1 (en) 2010-07-08
US20140308684A1 (en) 2014-10-16
EP3264080A2 (en) 2018-01-03
HK1243768A1 (zh) 2018-07-20
EP3264080A3 (en) 2018-03-21
WO2010078514A3 (en) 2010-10-28
HRP20181685T1 (hr) 2019-01-11
US10260084B2 (en) 2019-04-16
HUE040146T2 (hu) 2019-02-28
US20130149729A1 (en) 2013-06-13
US20190249224A1 (en) 2019-08-15
US20170321246A1 (en) 2017-11-09
ES2694047T3 (es) 2018-12-17

Similar Documents

Publication Publication Date Title
CY1121382T1 (el) Ποσοτικοποιηση υπολειμματικων ενωσεων γλυκανης με μη-αναγωγικα ακρα
GB2535414A (en) Sanitary tissue products with superior machine direction elongation and foreshortening properties and methods for making same
ATE554978T1 (de) Überwachungseinrichtung zur überwachung von systemen eines fahrzeugs
GB2540668A (en) Sanitary tissue products with free fibers and methods for making same
CY1118871T1 (el) Μεθοδος για διαγνωση διαταραχης mps iiib
CY1123643T1 (el) Υποβρυχια μοναδα επεξεργασιας νερου και μεθοδος καθαρισμου της εν λογω μοναδας
EA201300513A1 (ru) Волокна для контролируемого разложения
CY1122711T1 (el) Μεθοδος για την ενεργοποιηση και τη συζευξη βιομοριων
CY1117086T1 (el) Νεος συνδυασμος
CY1117490T1 (el) Μεθοδος παραγωγης της μεδετομιδινης
CY1116213T1 (el) Διαγνωστικα απεικονισης με συνδυασμο σκιαγραφικων
TN2015000263A1 (fr) Acute kidney injury
CY1121100T1 (el) Ποσοτικοποιηση υπολειμματικων ενωσεων γλυκανων μη-αναγωγικων ακρων
CL2009001973S1 (es) Mostrador.
CY1117044T1 (el) Μεθοδος παρασκευης κατωτερων υδρογονανθρακων απο γλυκερολη
FI20085769A (fi) Menetelmä kuiturainan ominaisuuksien optimoimiseksi
DK2464767T3 (da) Tekstilforbindelser
BRPI1014007A2 (pt) aparelho para seleção de suspensões de fibra.
PA8849101A1 (es) Procedimiento de preparación del hemifumarato de eplivanserina
GB202020041D0 (en) Monitoring arrangement
TR201002403A2 (tr) Buluşumuz ram makinelerinde kurutma için kullanılabilen bir düze sistemi.
IT1397134B1 (it) Filiera produttiva del settore tessile.
CL2009001216S1 (es) Perfil.
CY1117455T1 (el) Μεθοδος για τον καθαρισμο φαρμακευτικα αποδεκτων αλατων εσiταλοπραμης
CL2008000265S1 (es) Perfil.